Amelia K. Fotheringham

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
This Article contains errors in the Acknowledgements section. " The authors acknowledge funding support from the National Health and Medical Council of Australia (1004926). " should read: " The authors acknowledge funding support from the National Health and Medical Research Council of Australia (1004926) and Diabetes Australia. " This work is licensed(More)
Blood glucose control is the primary strategy to prevent complications in diabetes. At the onset of kidney disease, therapies that inhibit components of the renin angiotensin system (RAS) are also indicated, but these approaches are not wholly effective. Here, we show that once daily administration of the novel glucose lowering agent, empagliflozin, an(More)
  • 1